Orion Pharma 2nd-qtr net sales up 8.1%
Finnish drugmaker Orion Pharma has posted an 8.1% rise in second-quarter2001 net sales to 230.5 million euros ($203.3 million). Product sales expanded more rapidly than in the first quarter but the international business turned out at a lower level than expected. Profits improved after a poor first quarter. Marketing efforts focused on the heart-failure drug Simdax (levosimendan), the Parkinson drug Comtess (entacapone), the hormone replacement therapy Indivina and the Easyhaler range of asthma products.
The best-selling international drug products in the reporting quarter were Comtess/Comtan, the firm's HRT products and the breast cancer treatment Fareston (toremifene). Turnover of products from Orion's own R&D pipeline reached 62.1 million euros, or 26.9% of the division's net total. Combined sales of Comtess and Comtan were 25.8 million euros. The majority of sales of Fareston were achieved in Japan, while the French market led sales of the Easyhaler inhaler range.
Finnish market up 12.1% in 1st-half
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze